R3 Stem Cell, a top regenerative medicine company, announced the publication of a systematic review by its Research ...

Researchers at the University of Toronto found Canadian visits to US cities fell by nearly half in the year following the ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data demonstrating that a ...

What are the first steps that chart the path for a cell to become a blood cell, neuron cell, or pigment cell? Scientists have developed increasingly powerful tools to track those changes, but one ...

A new data center has been proposed in Chantilly that would rely on fuel cell technology to convert natural gas into ...

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models ...

Until now, studying the genetic processes in cells required destroying them—making it impossible to observe these processes ...

People report that their personal contact info was surfaced by Google AI—and there’s apparently no easy way to prevent it.

Beqalzi (sonrotoclax) is the first BCL2 inhibitor indicated for MCL patients who have progressed after at least 2 lines of therapy, including a BTK inhibitor.

Researchers develop IRISeq and EnrichSci to map cellular neighborhoods and analyze rare aging cells in the brain simultaneously.

BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, ...